Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Implantable Microdevice for in Situ Evaluation of Drug Responses in Lung Cancer
NCT07892300Phase 1Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Oct 2030
01
Overview
Phase 1, open-label, single-arm trial. Primary endpoint: Safety of microdevice implantation and indwelling at 30 days. Planned start Oct 2026; status: not yet recruiting.
Beyond the preview
Go deeper on NCT07892300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07892300.